Zacks: Evotec AG (EVTCY) Given Average Rating of “Strong Buy” by Brokerages
Evotec AG (NASDAQ:EVTCY) has been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Zacks has also assigned Evotec AG an industry rank of 99 out of 265 based on the ratings given to related companies.
A number of brokerages have recently issued reports on EVTCY. Zacks Investment Research raised Evotec AG from a “hold” rating to a “strong-buy” rating and set a $11.00 price target on the stock in a research report on Friday, August 12th. DZ Bank AG reaffirmed a “buy” rating on shares of Evotec AG in a research report on Monday, July 11th.
Evotec AG (NASDAQ:EVTCY) traded down 0.68% during midday trading on Wednesday, reaching $10.99. The company’s stock had a trading volume of 263 shares. The stock has a market cap of $728.35 million and a price-to-earnings ratio of 124.89. The stock’s 50 day moving average price is $10.63 and its 200-day moving average price is $9.09. Evotec AG has a one year low of $6.56 and a one year high of $11.54.
About Evotec AG
Evotec AG (Evotec) is a drug discovery and development company. The Company is engaged in providing drug discovery solutions to the pharmaceutical, biotechnology and academic sectors. The Company has two segments: EVT Execute and EVT Innovate. EVT Execute segment offers stand-alone or integrated drug discovery solutions for collaborator’s targets and programs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.